← Back to Drugs A–Z

Tapentadol

Nicknames: Palexia, Tapenta
Last reviewed: October 2026

History

Tapentadol was first synthesised by chemist Helmut Buschmann and colleagues in the late 1980s at the German pharmaceutical company Grünenthal GmbH as a successor to tramadol with minimal serotonin activity. In 2010, the ACMD advised the UK government to control tapentadol as a Class A, Schedule II drug before it became available for clinical use. In May 2011, tapentadol was brought to the UK pharmaceutical market under the brand name Palexia for the treatment of severe chronic pain.

Between 2014 and 2022, as tramadol prescribing decreased, tapentadol prescriptions increased in England and Ireland by 179% and 389%, respectively. Additionally, some people seek tapentadol on the unregulated market either for recreational purposes or to self-medicate for unmet needs including pain. In recent years, tapentadol has been found as a contaminant in several samples from the UK’s unregulated drugs market including heroin, tramadol, modafinil, lorazepam, and morphine.

Keep This Information Independent

Release is a registered charity. We rely on your support to provide expert, non-judgmental legal and harm reduction guidance to thousands of people every year.

Donate to Release